I have written a function to calculate the Runge-Kutta numerical approximation of the differential equation dy/dt = -2ty^2 w/ initial conditions y(0)=1 from t=0 to t=10. The function worked when I ...

Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. This investment ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

The artificial-intelligence-powered drug designer Recursion signed on to a wide-ranging collaboration with Roche and its Genentech division. Starting with a hefty $150 million upfront payment, the ...

Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...

Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ: RXRX). The company has emerged as a ...

This biotech could still be a long way from having a drug on the market in 2026. But at the moment, it's burning cash like wild, and there's no sign of when that'll end, as it has nothing in the way ...

The investing party is the Wall Street darling chipmaker of the moment, Nvidia (NASDAQ: NVDA). It disclosed that as of Dec. 31, it held investments in three companies developing artificial ...

RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...

Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The company reported a quarterly loss of 42 cents per share, which beat estimates ...